Improving drug delivery for recurrent glioblastoma patients
Comparison of convection enhanced delivery systems in a randomized controlled clinical study of recurrent Grade 3-4 glioma patients
This study is testing a new way to deliver cancer treatments directly to glioblastoma tumors using a special catheter, and it's for patients who are looking for better options to fight this tough type of brain cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creosalus, INC. NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11006772 on NIH RePORTER |
What this research studies
This research investigates a new method for delivering cancer treatments directly to glioblastoma tumors using a specialized catheter system. The approach involves convection enhanced delivery (CED) technology, which aims to improve the distribution of therapeutic agents within the tumor. Patients will be randomly assigned to receive treatment through either a new porous catheter or a standard catheter, allowing researchers to compare the effectiveness of these methods. The study also utilizes advanced software to simulate and plan the infusion process, ensuring precise delivery of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent Grade 3-4 glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not experiencing recurrence of glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with recurrent glioblastoma, potentially improving their outcomes and quality of life.
How similar studies have performed: Previous research has shown promise in using convection enhanced delivery systems for brain tumors, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Louisville, United States
- Creosalus, INC. — Louisville, United States (Active)
Researchers
- Principal investigator: Abramov, Vasiliy — Creosalus, INC.
- Study coordinator: Abramov, Vasiliy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.